| U.S. Brand Names |
| Cesamet® |
 |
| Generic Available |
|
No |
|
| Pharmacological Index |
|
Antiemetic |
|
| Use |
|
Treatment of nausea and vomiting associated with cancer chemotherapy |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Nausea and vomiting not secondary to cancer chemotherapy |
|
| Adverse Reactions |
|
>10%: Central nervous system: Dizziness, drowsiness, vertigo, euphoria, clumsiness Gastrointestinal: Xerostomia 1% to 10%: Cardiovascular: Orthostatic hypotension Central nervous system: Ataxia, depression Ocular: Blurred vision |
|
| Drug Interactions |
|
CNS depression is potentiated with ethanol |
|
| Mechanism of Action |
|
Nabilone is a synthetic cannabinoid utilized as an antiemetic drug in the control of nausea and vomiting in patients receiving cancer chemotherapy; like delta-9-tetrahydrocannabinol (the active principal of marijuana), nabilone is a dibenzo(b,d)pyrans |
|
| Pharmacodynamics/Kinetics |
|
Absorption: Rapid Serum half-life: 35 hours |
|
| Usual Dosage |
|
Oral: <18 kg: 0.5 mg twice daily 18-30 kg: 1 mg twice daily >30 kg: 1 mg 3 times/day Adults: 1-2 mg twice daily beginning 1-3 hours before chemotherapy is administered and continuing around-the-clock until 1 dose after chemotherapy is completed; maximum daily dose: 6 mg divided in 3 doses |
|
| Mental Health: Effects on Mental Status |
|
Dizziness, drowsiness, and euphoria are common; may cause depression; may rarely cause confusion and hallucinations |
|
| Mental Health: Effects on Psychiatric Treatment |
|
Concurrent use with psychotropic may produce additive sedation |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
>10% of patients experience dry mouth |
|
| Patient Information |
|
May cause drowsiness, impair judgment, coordination; avoid alcohol and other CNS depressants; can cause disorientation |
|
| Dosage Forms |
|
Capsule: 1 mg |
|
|
Copyright © 2007 Drugs Area |
